PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Am J Hematol. Author manuscript; available in PMC 2018 January 1.
Published in final edited form as:
Am J Hematol. 2017 January; 92(1): E3–E4.
Published online 2016 November 18. doi:  10.1002/ajh.24579
PMCID: PMC5551407
NIHMSID: NIHMS891636

Clinical characteristics of Philadelphia positive T-cell lymphoid leukemias – (de novo and blast phase CML)

The Philadelphia chromosome (Ph+) is a hallmark of CML and is also present in a subset of patients with acute lymphoblastic leukemia (ALL). Patients presenting with clinical features of T cell lineage leukemia and Ph chromosome can suggest either a T-ALL or lymphoid blast phase of CML with T-lineage.14 Lymphoid blast phase (CML-BP) and Ph+ ALL almost always affect B cell lineage and very rarely involve T cell lineage or present with mixed phenotype5. It is unclear as to how the presence of Ph chromosome or BCR-ABL protein is associated in regulating the differentiation or the lineage switch of leukemic stem cells. Presence of Ph+ is documented in precursor B cells from CML patients in chronic phase.6

In this report, we present the clinical characteristics of the rare subset of patients with Ph+ ALL or CML-BP with T-cell lymphoid phenotype. We reviewed the institutional database for all patients with blast phase CML (n=498) and de novo T-ALL (n=150) diagnosed since 07/1997. All clinical characteristics at the time of the diagnosis of BP or Ph+ ALL and treatment course were collected. Seven patients with Ph+ T-cell lymphoid leukemia were identified.

Among the total of 498 CML-BP patients, 5 patients had T-cell lymphoid CML-BP (0.01%); in addition 2 patients with de novo Ph+ T-ALL were identified among 150 patients with T-ALL seen during the same time period (1.3%). Median age of the seven patients was 57 years (range 31–72 years); 71% were male. Among patients with CML-BP, all were in BP at the time they were referred to our institution (one had progressed from an initial diagnosis in CP, 1 from accelerated phase, and 3 were in BP at initial diagnosis). Only 2 patients with CML-BP received prior TKI therapy; the 2 patients with T-ALL were previously untreated at the time of referral. Immunophenotype included 2 cortical, 3 early T-cell and 2 early T-cell precursor; 2 patients were negative and one was dim positive for TdT (summarized in Table-1). Extramedullary disease at initial presentation was seen in all patients [2 with lymphadenopathy alone, 2 with mediastinal involvement (one also with lymphadenopathy and the other with splenomegaly and lymphadenopathy), 2 with pleural effusion (1 with lymphadenopathy and another with splenomegaly) and 1 patient with splenomegaly alone]. None had central nervous system (CNS) involvement at initial presentation, but one patient developed CNS involvement at first relapse. One patient had variant Ph+ and 2 had complex karyotype. Three patients had lymphoblastic lymphoma and 4 patients had T-ALL. Five patients died (3 from disease progression, one from complications of stem cell transplantation (SCT), and one from intestinal obstruction and sepsis) and 2 are alive (25 and 49 months from BP diagnosis). The median survival for all patients was 13 months (range 1–49 months).

Table 1
Summary of patients with Ph+ T-cell lymphoid leukemia’s (CML-BP) and denovo T-ALL

Five patients received hyper-CVAD based therapy as an induction regimen: 3 of them received hyper-CVAD alone – one achieved CR then underwent a SCT but died due to complications of SCT, another achieved PR and was given imatinib followed by dasatinib which he did not tolerate; he was subsequently lost to follow up; and one patient had no response. The other 2 patients received hyper-CVAD with dasatinib – one achieved PR, then underwent allo-SCT and achieved CR but later had a CNS relapse and progressed; the other patient developed nodal progression 9 months after achieving CR with HCVAD-dasatinib which was later found to represent metastatic prostate cancer in the lymph nodes with no T-ALL recurrence and is currently on dasatinib with major molecular response. Two patients never received any TKI (tyrosine kinase inhibitor) therapy and progressed on chemotherapy alone. Two patients received nelarabine as first salvage – one as a single agent (no response) and another with dasatinib (with PR).

According to the literature, <50 cases of T-lineage acute leukemia with Ph chromosome have been reported, mainly as an anecdotal case report.7,8 These included a mixture of patients with T-ALL and/or lymphoid blast phase CML. Extramedullary involvement with lymph nodes, mediastinum, liver and spleen was frequent1 and outcomes were dismal. T-cell lymphoid CML-BP has been described in the past.5 A diagnosis of prior CML was not observed in all patients with T-cell lymphoid CML-BP but majority of these patients had a prior CML. It is difficult to differentiate between T-cell lymphoid CML-BP vs a denovo T-ALL, however features which favor the T-cell lymphoid CML-BP over denovo T-ALL are history of prior CML, presence of non-e1a2 BCR-ABL transcripts, adult age group, extramedullary disease, absence of lymphoblastic leukemia in the bone marrow and excellent response to therapy with second generation TKI combined with intensive chemotherapy HCVAD.

In our experience, Ph+ T-cell lymphoid leukemias are extremely rare and have clinical features similar to those of de novo T-ALL. Pathogenesis of T cell lineage differentiation of leukemic stem cells in adults with Ph+ leukemias is unclear. Outcomes of these patients are generally poor, however induction with a combination of HCVAD and second generation TKI’s may achieve prolonged remission in some patients.

Acknowledgments

This study was supported in part by the NIH/NCI under award number P30CA016672 and by the NCI under award number P01CA049639.

Footnotes

Authorship Contributions

P.J., and J.C. Contributed to the study design, data collection, wrote the paper and analyzed results. R. K-S., H.K., K.P. and S.P., analyzed molecular data, H.K., F.R., E.J., G.B., G.M.G., S.O.B., and J.C. contributed patient samples.

Conflicts-of-Interest Disclosure: None from any authors.

References

1. Wei J, Huang M, Wang Y, Zhou J. Sudden extramedullary blast crisis of chronic myeloid leukemia manifesting as T-cell lymphoblastic lymphoma. Onkologie. 2013;36(3):119–122. [PubMed]
2. Raanani P, Trakhtenbrot L, Rechavi G, et al. Philadelphia-chromosome-positive T-lymphoblastic leukemia: acute leukemia or chronic myelogenous leukemia blastic crisis. Acta Haematol. 2005;113(3):181–189. [PubMed]
3. Okazuka K, Toba K, Kawai K, et al. Extramedullary T lymphoid blast crisis representing an additional translocation, t(6;8)(q25;q22) in a patient with Philadelphia-positive chronic myelogenous leukemia after allogeneic bone marrow transplantation. Leuk Res. 2001;25(12):1089–1094. [PubMed]
4. Gramatzki M, Bartram CR, Muller D, Walter M, Tittelbach H, Kalden JR. Early T cell differentiated chronic myeloid leukemia blast crisis with rearrangement of the breakpoint cluster region but not of the T cell receptor beta chain genes. Blood. 1987;69(4):1082–1086. [PubMed]
5. Akashi K, Mizuno S, Harada M, et al. T lymphoid/myeloid bilineal crisis in chronic myelogenous leukemia. Exp Hematol. 1993;21(6):743–748. [PubMed]
6. Bernheim A, Berger R, Preud’homme JL, Labaume S, Bussel A, Barot-Ciorbaru R. Philadelphia chromosome positive blood B lymphocytes in chronic myelocytic leukemia. Leuk Res. 1981;5(4–5):331–339. [PubMed]
7. Dorfman DM, Longtine JA, Fox EA, Weinberg DS, Pinkus GS. T-cell blast crisis in chronic myelogenous leukemia. Immunophenotypic and molecular biologic findings. Am J Clin Pathol. 1997;107(2):168–176. [PubMed]
8. Fabbiano F, Santoro A, Felice R, Catania P, Cannella S, Majolino I. bcr-abl rearrangement in adult T-lineage acute lymphoblastic leukemia. Haematologica. 1998;83(9):856–857. [PubMed]